middl
east
respiratori
syndrom
coronaviru
mer
cov
may
caus
sever
pneumonia
signific
morbid
mortal
particularli
patient
multipl
comorbid
condit
mer
cov
pneumonia
previous
report
patient
human
immunodefici
viru
hiv
herein
report
case
mer
cov
pneumonia
success
outcom
patient
recent
diagnos
hiv
elsevi
bv
right
reserv
middl
east
respiratori
syndrom
coronaviru
mer
cov
pneumonia
report
mortal
gener
popul
previou
report
mer
cov
pneumonia
patient
posit
human
immunodefici
viru
hiv
immunosuppress
effect
hiv
well
steroid
may
lead
dissemin
viral
infect
howev
previou
data
mer
cov
pneumonia
patient
low
count
due
hiv
steroid
lack
herein
report
mer
cov
pneumonia
patient
recent
diagnos
hiv
prednison
pneumocysti
jirovecii
pneumonia
pjp
april
year
old
gentleman
admit
short
breath
dri
cough
diffus
pulmonari
infiltr
radiolog
imag
hiv
elisa
test
posit
subsequ
confirm
posit
western
blot
trimethoprimsulfamethoxazol
tmpsx
mg
oral
everi
hour
addit
prednison
mg
daili
initi
empir
treat
pjp
pneumonia
patient
symptom
rapidli
improv
sent
home
mention
treatment
start
antiretrovir
treatment
count
yet
avail
point
moreov
diagnosi
pjp
presumpt
one
sputum
sampl
could
collect
bronchoscopi
done
view
rapid
improv
patient
clinic
condit
respons
tmpsx
admit
fifteen
day
later
two
day
histori
fever
short
breath
product
cough
recent
contact
camel
peopl
similar
ill
physic
examin
reveal
temperatur
c
respiratori
rate
min
blood
pressur
auscult
reveal
bilater
vesicular
breath
ad
sound
blood
examin
reveal
white
blood
cell
count
l
absolut
neutrophil
count
l
absolut
lymphocyt
count
l
hemoglobin
gdl
platelet
count
lactat
dehydrogenas
ul
creactiv
protein
crp
mgl
alanin
aminotransferas
alt
ul
plasma
hiv
viral
load
revers
transcript
polymeras
chain
reaction
rtpcr
copiesml
coba
amplicor
assay
remaind
patient
laboratori
test
essenti
normal
serolog
test
cytomegaloviru
cmv
epstein
barr
viru
ebv
reveal
past
infect
chest
xray
reveal
patchi
air
space
opac
right
lower
lobe
fig
diagnosi
mer
cov
pneumonia
confirm
use
two
real
time
rtpcr
assay
one
target
upstream
e
protein
gene
upe
target
region
within
open
read
frame
orf
sputum
sampl
april
rtpcr
test
done
light
cycler
machin
place
isol
room
start
combin
interferon
cg
subcutan
weekli
combin
ribavirin
load
dose
gm
follow
mg
oral
everi
hour
upon
complet
pjp
treatment
tmpsx
dose
reduc
secondari
prophylaxi
dose
mg
oral
daili
base
recent
data
regard
superior
vitro
efficaci
interferon
due
lack
improv
patient
clinic
condit
interferon
switch
interferon
cg
subcutan
three
time
weekli
ribavirin
continu
tcell
subset
test
reveal
count
cell
lmm
count
cell
lmm
ratio
patient
promptli
start
antiretrovir
treatment
consist
combin
tenofoviremtricitabin
tdfftc
mg
oral
daili
combin
ritonavir
boost
atazanavir
atazanvir
mg
addit
ritonavir
mg
oral
daili
patient
complain
increas
sputum
product
oxygen
requir
increas
maximum
lmin
sputum
cultur
reveal
e
coli
treat
meropenem
per
suscept
studi
patient
respiratori
symptom
oxygen
requir
subsequ
improv
hospit
admiss
cours
complic
persist
diarrhea
bacteri
stool
cultur
clostridium
difficil
pcr
stool
microscopi
ova
parasit
neg
serum
cytomegaloviru
cmv
quantit
pcr
copiesml
comput
tomographi
ct
abdomen
reveal
circumferenti
recto
sigmoid
wall
thicken
ganciclovir
mgkg
intraven
everi
hour
promptli
initi
treat
cmv
coliti
follow
valganciclovir
mg
oral
twice
daili
diarrhea
resolv
four
day
initi
ganciclovir
cytomegaloviru
treatment
administ
total
day
serial
sputum
mer
cov
pcr
test
done
day
interv
determin
durat
mer
cov
shed
persist
posit
june
fig
two
consecut
sputum
sampl
neg
mer
cov
pcr
day
apart
patient
oxygen
satur
room
air
patient
becam
depress
least
partial
attribut
interferon
treatment
therefor
interferon
ribavirin
discontinu
prior
achiev
neg
respiratori
tract
rtpcr
receiv
interferon
follow
interferon
combin
ribavirin
total
durat
day
respect
patient
clinic
well
radiolog
improv
evidenc
resolut
air
space
opac
residu
atelectasi
resolv
follow
chest
xray
juli
went
home
mention
antiretrovir
treatment
addit
prophylact
trimethoprimsulfamethoxazol
mg
daili
tcell
subset
repeat
june
reveal
count
cell
lmm
count
cell
lmm
ratio
previous
report
case
describ
mer
cov
infect
hiv
posit
patient
pneumonia
caus
mer
cov
associ
signific
morbid
mortal
effect
hiv
low
count
cours
mer
cov
ill
unknown
report
success
recoveri
patient
hivaid
mer
cov
pneumonia
clinic
present
patient
mer
cov
pneumonia
similar
previous
report
nonhiv
infect
cohort
term
symptom
laboratori
radiolog
abnorm
given
patient
lack
contact
similarli
ill
patient
home
recent
hospit
admiss
period
sever
patient
confirm
mer
cov
infect
like
patient
contract
viru
hospit
stay
patient
continu
shed
mer
cov
evidenc
persist
posit
mer
cov
rtpcr
sputum
sampl
day
helper
cell
play
integr
role
initi
effect
immun
respons
clear
mer
cov
viral
shed
posit
mer
cov
rtpcr
sputum
sampl
prolong
immunocompromis
patient
compar
healthi
individu
case
season
influenza
well
viru
case
seri
six
hivinfect
individu
viru
detect
rtpcr
day
start
treatment
oseltamivir
howev
sinc
data
exist
regard
durat
mer
cov
shed
immunocompet
popul
difficult
determin
whether
durat
shed
patient
prolong
whether
patient
low
count
addit
steroid
slow
clearanc
mer
cov
decis
initi
treat
interferon
combin
ribavirin
base
vitro
studi
show
strong
inhibitori
effect
interferon
mer
cov
replic
support
studi
anim
model
receiv
earli
treatment
interferon
combin
ribavirin
interferon
use
instead
interferon
due
lack
avail
latter
may
play
role
initi
lack
improv
patient
clinic
condit
moreov
recent
data
hart
et
al
demonstr
superior
vitro
activ
interferon
compar
differ
interferon
product
includ
interferon
therefor
view
lack
improv
patient
clinic
condit
coupl
persist
sputum
sampl
posit
mer
cov
pcr
decis
made
switch
interferon
interferon
given
lack
data
regard
effect
dose
initi
therapi
interferon
cg
subcutan
time
weekli
human
data
avail
util
combin
interferon
ribavirin
case
seri
patient
mortal
rate
human
data
regard
efficaci
interferon
combin
ribavirin
treat
mer
cov
pneumonia
therefor
possibl
simpli
attribut
success
outcom
patient
treatment
nonetheless
interferon
interferon
necessari
activ
tcell
respons
mayb
possibl
exogen
administr
interferon
follow
interferon
led
activ
cell
henc
aid
subsequ
clearanc
mer
cov
viru
howev
verifi
prospect
control
manner
summari
report
success
recoveri
patient
hivaid
mer
cov
pneumonia
date
report
case
mer
cov
pneumonia
patient
hivaid
differ
viral
shed
durat
immunocompet
immunocompromis
patient
impact
treatment
decis
deserv
evalu
compar
studi
futur
research
direct
address
effect
hiv
posit
clinic
cours
mer
cov
infect
larg
cohort
particularli
relat
vari
count
addit
efficaci
exogen
interferon
interferon
combin
ribavirin
test
prospect
random
control
manner
ss
review
literatur
written
manuscript
rs
az
provid
aid
interpret
molecular
virolog
result
contribut
manuscript
contribut
manuscript
author
approv
final
manuscript
none
none
declar
requir
